吉西他滨、紫杉醇联合顺铂治疗晚期尿路上皮癌的近期疗效观察被引量：4

Observation of the Short-term Efficacy of Gemcitabine,Paclitaxel plus Cisplatin in the Treatment of Advanced Urothelial Carcinoma

原文传递

导出

摘要目的初步分析吉西他滨、紫杉醇联合顺铂(GTP)的化学疗法(化疗)方案在中国晚期尿路上皮癌患者的疗效及不良反应。方法收集2014年2月-7月期间在采用GTP方案化疗的晚期尿路上皮癌患者10例,按实体瘤的疗效评价标准1.1评价客观疗效收集不良反应。结果 10例晚期尿路上皮癌患者采用GTP方案进行一线化疗,完全缓解1例,部分缓解4例,稳定3例,进展2例。Ⅲ度的不良反应主要为血液学毒性,其中Ⅲ度白细胞或中性粒细胞下降5例,Ⅲ度贫血1例。其余不良反应包括胃肠道反应、脱发和肝肾功能异常等。结论 GTP方案治疗晚期尿路上皮癌近期疗效好,不良反应可控制,患者可耐受。 Objective To evaluate the efficacy and toxicity of gemcitabine,paclitaxel plus cisplatin（GTP） chemotherapy for advanced urothelial carcinoma in China.Methods Ten patients with advanced urothelial carcinoma who underwent GTP chemotherapy regimens were collected from February to July 2014 in our hospital.According to solid tumor curative effect evaluation standard 1.1,we evaluated the clinical efficacy and collected the adverse reactions.Results Ten patients with advanced urothelial carcinoma accepted first-line chemotherapy using GTP chemotherapy regimens.There was 1 case of complete remission,4 cases of partial response,3 stable cases,and 2 progressive cases.Adverse reactions of degree Ⅲ were mainly of hematology toxicity,including 5 cases of leukocytes and neutrophils reduction,and 1 case of anemia.The remaining adverse reactions included gastrointestinal reaction,hair loss,and abnormal renal function.Conclusion GTP chemotherapy regimen is a promising treatment for advanced urothelial carcinoma.

作者何建萍陈烨郭春红罗无瑕李丛刘继彦

机构地区四川大学华西医院肿瘤中心腹部肿瘤科

出处《华西医学》 CAS 2015年第7期1226-1229,共4页 West China Medical Journal

关键词吉西他滨紫杉醇顺铂晚期尿路上皮癌 Gemcitabine Taxol Cisplatin Advanced urothelial carcinoma

分类号 R737 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer[J]. Semin in Oncol, 2012, 39(5): 598-607.
2Stadler WM, Kuzel T, Roth B, et al. A phase Ⅱ study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer[J]. J Clin Oncol, 1997, 15(11): 3394-3398.
3Greene FL, PageDL, Fleming ID, et al. AJCC Cancer Staging Manual[M]. 6th ed. AJCC New York, Berlin, Heidelberg: Springer-Verlag, 2002.
4Sternberg CN, Yagoda A, Scher HL, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium[J]. J Urol, 1985, 133(3): 403-407.
5Sternberg CN. A critical review of the management of bladder cancer[J]. Crit Rev Oncol Hematol, 1999, 31(3): 197-207.
6Von der Maase H, Hanse SW, Roberts JT, et al. Gemcitabine and cispatin in advanced or metastatic bladder cancer: resuits of a large randomized multicenter, multinational multicenter, phase Ⅲ study[J]. J Clin Oncol, 2000, 18(17): 3068-3077.
7Sternberg CN, De Mulder P, Schornagel JH, et al. Seven year update of EORTC phase Ⅲ trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors[J]. Eur J Cancer, 2006, 42(1): 50-54.
8Bellmunt J, von der Masse H, Mead G, et al. Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/ cisplatin in patients with locally advanced or mestastatic urothelial cancer without prior systemic therapy; EORTC intergroup study 30987[J]. J Clin Oncol, 2012, 30(10): 1107-1113.